ERYP Erytech Pharma S.A.

4.02
0  0%
Previous Close 4.02
Open
Price To Book 0.56
Market Cap 72,108,891
Shares 17,937,535
Volume 0
Short Ratio
Av. Daily Volume 416
Stock charts supplied by TradingView

NewsSee all news

  1. Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2019

    LYON, France, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol

  2. ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019

    Conference call and webcast on Wednesday, September 18at 2:30 pm CET/8:30 am EDT TRYbeCA1, Phase 3 trial for eryaspase in second line pancreatic cancer, progressing on planImmune modulation collaboration entered into

  3. ERYTECH to Host Second Quarter 2019 Conference Call and Business Update

    LYON, France, Sept. 11, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood

  4. Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2019

    LYON, France, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial completed.
Hydro-Lido
Hemorrhoids
Phase 3 enrolment has commenced - noted September 20, 2018.
Eryaspase (GRASPA)
Pancreatic cancer
Phase 2 data due 1H 2020.
Eryaspase (GRASPA)
Acute lymphoblastic leukemia (ALL) - front line
Phase 2 dosing has commenced - noted June 26, 2019. Interim data due estimated 1H 2020.
Eryaspase (GRASPA) - TRYbeCA2
Triple-Negative Breast Cancer (TNBC)

Latest News

  1. Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2019

    LYON, France, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol

  2. ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019

    Conference call and webcast on Wednesday, September 18at 2:30 pm CET/8:30 am EDT TRYbeCA1, Phase 3 trial for eryaspase in second line pancreatic cancer, progressing on planImmune modulation collaboration entered into

  3. ERYTECH to Host Second Quarter 2019 Conference Call and Business Update

    LYON, France, Sept. 11, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood

  4. Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2019

    LYON, France, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States